Clinical trial
Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory…
NCT00002659 · Matrix Pharmaceutical, Industry · Unknown status
Key facts
| NCT number | NCT00002659 |
|---|---|
| Title | Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer |
| Official title | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK |
| Lead sponsor | Matrix Pharmaceutical, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | cisplatin-e therapeutic implant |
| Enrollment | 120 |
| Start date | May 1, 1995 |
| First posted | Aug 31, 2004 |
| Last update posted | Dec 19, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: